Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2420 plus somatostatin analogs in acromegaly (Phase II, China)
CTR20260054Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of AZP-3813 in acromegaly, sponsored by Alexion Pharmaceuticals. Started Jan 2026; status: terminated.
02
Drugs
AZP-3813
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20260054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260054.